OBJECTIVE: to know ambulatory blood pressure control status of diabetic patients with hypertension and provide information for antihypertensive therapy.
目的:了解糖尿病合并高血压患者的动态血压控制状况,为降压治疗提供依据。
Objective: To study the relationship between hypertension and insulin resistance and plasma adrenomedullin endothelin changes in diabetic patients with hypertension.
目的:探讨胰岛素抵抗、血浆肾上腺髓质素、内皮素与糖尿病合并高血压的关系。
The changes, however, "did not lead to substantially better hypertension control for diabetics compared with non-diabetic patients," the researchers concluded.
这些策略上的改变,“同非糖尿病患者相比,并未改善糖尿病患者的高血压控制,”研究人员总结道。
Conclusion:Allele T of AGT gene M235T, the longer diabetes duration and history of hypertension were associated with higher risk of nephropathy in type 2 diabetic patients.
结论:AGT基因235T等位基因、糖尿病病程长、既往高血压史均可增加2型糖尿病患者合并肾病的危险;
Method: Case control study was used to observe the changes of serum lipid levels in type 2 diabetes patients and type 2 diabetic nephropathy patients with hypertension or normotension.
方法:采用病例对照研究的方法观察2型糖尿病、2型糖尿病肾病合并高血压和不合并高血压患者血脂水平的变化。
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria.
预测因子与2型糖尿病肾病和高血压患者心血管事件的预测因子:蛋白尿因素。
CONCLUSION Telmisartan is superior to losartan in reducing proteinuria in diabetic nephropathy patients with hypertension, despite a similar reduction in blood pressure.
结论:替米沙坦减轻糖尿病肾病患者蛋白尿优于氯沙坦。
Methods There 36 diabetic nephropathy patients complicated with refractory hypertension were treated with two different therapies and the results were observed before and after the treatment.
方法对36例糖尿病肾病合并顽固性高血压患者随机分为治疗组和对照组,观察两组治疗前后降压情况、副作用和实验证据变化。
Methods There 36 diabetic nephropathy patients complicated with refractory hypertension were treated with two different therapies and the results were observed before and after the treatment.
方法对36例糖尿病肾病合并顽固性高血压患者随机分为治疗组和对照组,观察两组治疗前后降压情况、副作用和实验证据变化。
应用推荐